Generalized glucocorticoid resistance

(Redirected from Glucocorticoid resistance) Medical condition

Generalized glucocorticoid resistance
Other names	Chrousos syndrome

Left. DNA-binding domains of a glucocorticoid receptor homodimer in the nucleus interacting with DNA. Right. Binding of synthetic glucocorticoid dexamethasone to ligand-binding domain of receptor in cytoplasm.
Specialty	Endocrinology

Generalized glucocorticoid resistance or Chrousos syndrome is a rare genetic disorder that can run in families or be sporadic. It is characterized by partial or generalized target-tissue insensitivity to glucocorticoids.

The clinical spectrum includes severe, potentially fatal conditions like hypoglycemia, alkalosis, or severe hypokalemia, as well as completely asymptomatic forms. The disease's most prevalent symptom is fatigue.

The elevated 24-hour urinary free cortisol (UFC) excretion in the absence of clinical signs of hypercortisolism and the elevated serum cortisol concentrations point to the diagnosis of generalized glucocorticoid resistance.

The goal of treatment for generalized glucocorticoid resistance is to reduce excessive ACTH secretion, which in turn reduces the production of more adrenal steroids that have androgenic and mineralocorticoid properties. High dosages of synthetic glucocorticoids that spare mineralocorticoids, like dexamethasone, are used as part of the treatment.

Signs and symptoms

Individuals who have generalized glucocorticoid resistance may exhibit biochemical hypercortisolism in the absence of Cushing's syndrome symptoms. The condition's clinical phenotype varies from cases with no symptoms to signs of excess mineralocorticoids in the body such as hypokalemic alkalosis and hypertension and/or androgen excess, including oligospermia in males, menstrual irregularities, hypo fertility, and amenorrhea in females, precocious puberty, male-pattern hair loss, acne, hirsutism, and ambiguous genitalia at birth with 46, XX.

In rare instances, glucocorticoid deficiency has been reported in the following cases: hypoglycemia, severe hypertension, easy "fatigability" with feeding, growth hormone deficiency, and generalized seizures in a 2-year-old girl, adult patients with chronic fatigue, and a newborn with hypoglycemia, hypokalemia, and increased arterial pressure.

Causes

De novo genetic defects (point mutations, deletions, or insertions) in the NR3C1 gene can cause sporadic cases of Chrousos syndrome, or it can be inherited in an autosomal recessive or dominant manner. Defective human glucocorticoid receptors in the hypothalamus and pituitary cause impaired glucocorticoid negative feedback loops in patients with Chrousos syndrome, which leads to compensatory hypersecretion of adrenocorticotropic hormone (ACTH), corticotropin-releasing hormone (CRH), and arginine vasopressin (AVP).

Mechanism

Steroid hormones known as "glucocorticoids" are produced in the zona fasciculata of the adrenal cortex and numerous other extra-adrenal organs, such as the skin, thymus, and gut. These lipophilic molecules are essential for the maintenance of both resting as well as threatened homeostasis and are secreted in the circulatory system in reaction to stressors and also in an ultradian and circadian manner.

Diagnosis

The elevated 24-hour urinary free cortisol (UFC) excretion with the absence of clinical signs of hypercortisolism and the elevated serum cortisol concentrations point to the diagnosis of generalized glucocorticoid resistance. ACTH plasma concentrations can range from low to high. To confirm the diagnosis, peripheral blood mononuclear cells must be used in thymidine incorporation and dexamethasone-binding assays in conjunction with sequencing of the human glucocorticoid receptor gene.

When diagnosing generalized glucocorticoid resistance, the differential diagnosis consists of additional factors that can lead to hyperandrogenism or virilization, including congenital adrenal hyperplasia, polycystic ovarian syndrome, and idiopathic hirsutism; hyperaldosteronism, essential hypertension, and additional mineralocorticoid-induced hypertensive disorders; circumstances like a typical pregnancy and estrogen therapy that are linked to increased serum concentrations of corticosteroid-binding globulin; pseudo-Cushing's conditions, like melancholic depression and generalized anxiety; and mild variations of Cushing's disease, in which normal or slightly elevated ACTH concentrations coexist with hypercortisolism.

Treatment

The goal of treatment for generalized glucocorticoid resistance is to reduce excessive ACTH secretion, which in turn reduces the production of more adrenal steroids that have androgenic and mineralocorticoid properties. High dosages of mineralocorticoid-sparing synthetic glucocorticoids, like dexamethasone, are used as a form of treatment to activate the mutant and/or wild-type hGRα and suppress the affected subjects' natural secretion of ACTH.

References

^ Chrousos, G P; Vingerhoeds, A; Brandon, D; Eil, C; Pugeat, M; DeVroede, M; Loriaux, D L; Lipsett, M B (June 1, 1982). "Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease". Journal of Clinical Investigation. 69 (6). American Society for Clinical Investigation: 1261–1269. doi:10.1172/jci110565. ISSN 0021-9738. PMC 370198. PMID 6282933.
Ruiz, Mini; Lind, Ulrika; Gåfvels, Mats; Eggertsen, Gösta; Carlstedt-Duke, Jan; Nilsson, Lennart; Holtmann, Martin; Stierna, Pontus; Wikström, Ann-Charlotte; Werner, Sigbritt (2001). "Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance". Clinical Endocrinology. 55 (3): 363–371. doi:10.1046/j.1365-2265.2001.01323.x. ISSN 0300-0664. PMID 11589680. S2CID 46080344.
^ Charmandari, Evangelia; Kino, Tomoshige; Ichijo, Takamasa; Chrousos, George P. (May 1, 2008). "Generalized Glucocorticoid Resistance: Clinical Aspects, Molecular Mechanisms, and Implications of a Rare Genetic Disorder". The Journal of Clinical Endocrinology & Metabolism. 93 (5). The Endocrine Society: 1563–1572. doi:10.1210/jc.2008-0040. ISSN 0021-972X. PMC 2386273. PMID 18319312.
^ KINO, TOMOSHIGE; VOTTERO, ALESSANDRA; CHARMANDARI, EVANGELIA; CHROUSOS, GEORGE P. (2002). "Familial/Sporadic Glucocorticoid Resistance Syndrome and Hypertension". Annals of the New York Academy of Sciences. 970 (1). Wiley: 101–111. Bibcode:2002NYASA.970..101K. doi:10.1111/j.1749-6632.2002.tb04416.x. ISSN 0077-8923. PMID 12381545. S2CID 6845457.
^ Chrousos, George P. (December 1, 1993). "Syndromes of Glucocorticoid Resistance". Annals of Internal Medicine. 119 (11). American College of Physicians: 1113–1124. doi:10.7326/0003-4819-119-11-199312010-00009. ISSN 0003-4819. PMID 8239231. S2CID 26040431.
^ Martins, Clarissa Silva; de Castro, Margaret (2021). "Generalized and tissue specific glucocorticoid resistance". Molecular and Cellular Endocrinology. 530. Elsevier BV: 111277. doi:10.1016/j.mce.2021.111277. ISSN 0303-7207. PMID 33864884. S2CID 233236063.
^ Nicolaides, Nicolas C.; Charmandari, Evangelia (October 7, 2021). "Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update". International Journal of Molecular Sciences. 22 (19). MDPI AG: 10839. doi:10.3390/ijms221910839. ISSN 1422-0067. PMC 8509180. PMID 34639183.
Nader, Nancy; Bachrach, Bert E.; Hurt, Darrell E.; Gajula, Sonia; Pittman, Amy; Lescher, Rachel; Kino, Tomoshige (May 1, 2010). "A Novel Point Mutation in Helix 10 of the Human Glucocorticoid Receptor Causes Generalized Glucocorticoid Resistance by Disrupting the Structure of the Ligand-Binding Domain". The Journal of Clinical Endocrinology & Metabolism. 95 (5). The Endocrine Society: 2281–2285. doi:10.1210/jc.2009-2463. ISSN 0021-972X. PMC 2869551. PMID 20335448.
McMahon, Sarah K.; Pretorius, Carel J.; Ungerer, Jacobus P. J.; Salmon, Nathaniel J.; Conwell, Louise S.; Pearen, Michael A.; Batch, Jennifer A. (2010). "Neonatal Complete Generalized Glucocorticoid Resistance and Growth Hormone Deficiency Caused by a Novel Homozygous Mutation in Helix 12 of the Ligand Binding Domain of the Glucocorticoid Receptor Gene (NR3C1)". The Journal of Clinical Endocrinology & Metabolism. 95 (1). The Endocrine Society: 297–302. doi:10.1210/jc.2009-1003. ISSN 0021-972X. PMID 19933394.
Nicolaides, Nicolas C.; Charmandari, Evangelia (2019). "Glucocorticoid Resistance". Experientia Supplementum. Vol. 111. Cham: Springer International Publishing. pp. 85–102. doi:10.1007/978-3-030-25905-1_6. ISBN 978-3-030-25904-4. ISSN 1664-431X. PMID 31588529. S2CID 203850229. {{cite book}}: |journal= ignored (help)
Slominski, Radomir M.; Tuckey, Robert C.; Manna, Pulak R.; Jetten, Anton M.; Postlethwaite, Arnold; Raman, Chander; Slominski, Andrzej T. (March 23, 2020). "Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders". Genes & Immunity. 21 (3). Springer Science and Business Media LLC: 150–168. doi:10.1038/s41435-020-0096-6. ISSN 1466-4879. PMC 7276297. PMID 32203088.
Stavrou, Stavroula; Nicolaides, Nicolas C.; Critselis, Elena; Darviri, Christina; Charmandari, Evangelia; Chrousos, George P. (February 3, 2017). "Paediatric stress: from neuroendocrinology to contemporary disorders". European Journal of Clinical Investigation. 47 (3). Wiley: 262–269. doi:10.1111/eci.12724. ISSN 0014-2972. PMID 28074555.
Nicolaides, Nicolas C.; Charmandari, Evangelia; Kino, Tomoshige; Chrousos, George P. (April 28, 2017). "Stress-Related and Circadian Secretion and Target Tissue Actions of Glucocorticoids: Impact on Health". Frontiers in Endocrinology. 8. Frontiers Media SA: 70. doi:10.3389/fendo.2017.00070. ISSN 1664-2392. PMC 5408025. PMID 28503165.
Focke, Caroline M.B.; Iremonger, Karl J. (2020). "Rhythmicity matters: Circadian and ultradian patterns of HPA axis activity". Molecular and Cellular Endocrinology. 501. Elsevier BV: 110652. doi:10.1016/j.mce.2019.110652. ISSN 0303-7207. PMID 31738971. S2CID 208021336.
Malchoff, D M; Brufsky, A; Reardon, G; McDermott, P; Javier, E C; Bergh, C H; Rowe, D; Malchoff, C D (May 1, 1993). "A mutation of the glucocorticoid receptor in primary cortisol resistance". Journal of Clinical Investigation. 91 (5). American Society for Clinical Investigation: 1918–1925. doi:10.1172/jci116410. ISSN 0021-9738. PMC 288186. PMID 7683692.

External links

Endotext

Classification	D ICD-11: 5A71.00 ICD-10: E25.8 ICD-9-CM: 255.2 OMIM: 615962 MeSH: C564221 DiseasesDB: 32669 SNOMED CT: 819950002
External resources	eMedicine: article/925564 GARD: Generalized glucocorticoid resistance syndrome Orphanet: 786

Genetic disorders relating to deficiencies of transcription factor or coregulators

(1) Basic domains

1.2	Feingold syndrome Saethre–Chotzen syndrome
1.3	Tietz syndrome

(2) Zinc finger
DNA-binding domains

2.1	(Intracellular receptor): Thyroid hormone resistance Androgen insensitivity syndrome PAIS MAIS CAIS Kennedy's disease PHA1AD pseudohypoaldosteronism Estrogen insensitivity syndrome X-linked adrenal hypoplasia congenita MODY 1 Familial partial lipodystrophy 3 SF1 XY gonadal dysgenesis
2.2	Barakat syndrome Tricho–rhino–phalangeal syndrome
2.3	Greig cephalopolysyndactyly syndrome/Pallister–Hall syndrome Denys–Drash syndrome Duane-radial ray syndrome MODY 7 MRX 89 Townes–Brocks syndrome Acrocallosal syndrome Myotonic dystrophy 2
2.5	Autoimmune polyendocrine syndrome type 1

(3) Helix-turn-helix domains

3.1	ARX Ohtahara syndrome Lissencephaly X2 MNX1 Currarino syndrome HOXD13 SPD1 synpolydactyly PDX1 MODY 4 LMX1B Nail–patella syndrome MSX1 Tooth and nail syndrome OFC5 PITX2 Axenfeld syndrome 1 POU4F3 DFNA15 POU3F4 DFNX2 ZEB1 Posterior polymorphous corneal dystrophy Fuchs' dystrophy 3 ZEB2 Mowat–Wilson syndrome
3.2	PAX2 Papillorenal syndrome PAX3 Waardenburg syndrome 1&3 PAX4 MODY 9 PAX6 Gillespie syndrome Coloboma of optic nerve PAX8 Congenital hypothyroidism 2 PAX9 STHAG3
3.3	FOXC1 Axenfeld syndrome 3 Iridogoniodysgenesis, dominant type FOXC2 Lymphedema–distichiasis syndrome FOXE1 Bamforth–Lazarus syndrome FOXE3 Anterior segment mesenchymal dysgenesis FOXF1 ACD/MPV FOXI1 Enlarged vestibular aqueduct FOXL2 Premature ovarian failure 3 FOXP3 IPEX
3.5	IRF6 Van der Woude syndrome Popliteal pterygium syndrome

(4) β-Scaffold factors
with minor groove contacts

4.2	Hyperimmunoglobulin E syndrome
4.3	Holt–Oram syndrome Li–Fraumeni syndrome Ulnar–mammary syndrome
4.7	Campomelic dysplasia MODY 3 MODY 5 SF1 SRY XY gonadal dysgenesis Premature ovarian failure 7 SOX10 Waardenburg syndrome 4c Yemenite deaf-blind hypopigmentation syndrome
4.11	Cleidocranial dysostosis

(0) Other transcription factors

0.6	Kabuki syndrome

Ungrouped

Transcription coregulators

Coactivator:	CREBBP Rubinstein–Taybi syndrome
Corepressor:	HR (Atrichia with papular lesions)

Adrenal gland disorder

Hyperfunction

Aldosterone	Hyperaldosteronism Primary aldosteronism Conn syndrome Bartter syndrome Glucocorticoid remediable aldosteronism AME Liddle's syndrome 17α CAH Pseudohypoaldosteronism
Cortisol	Cushing's syndrome Pseudo-Cushing's syndrome Steroid-induced osteoporosis
Sex hormones	21α CAH 11β CAH

Hypofunction

Aldosterone	Hypoaldosteronism 21α CAH 11β CAH
Cortisol	CAH Lipoid 3β 11β 17α 21α
Sex hormones	17α CAH Inborn errors of steroid metabolism
Adrenal insufficiency	Adrenal crisis Adrenalitis Xanthogranulomatous Addison's disease Waterhouse–Friderichsen syndrome

Categories:

Misplaced Pages